VF
RADX

Virtu Financial’s Radiopharm Theranostics RADX Stock Holding History

Virtu Financial’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,591
Closed -$76K – 2469
2025
Q4 		$76K Buy
+14,591
New +$77.7K ﹤0.01% 1252

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Virtu Financial's RADX Position: Q1 2026 in Review

Virtu Financial sold out of Radiopharm Theranostics (RADX) in Q1 2026, closing a stake of 14,591 shares — an estimated $76K sold.

Virtu Financial first reported a position in RADX in Q4 2025 and held it in 1 quarter. The position peaked at $76K in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • Virtu Financial reported no remaining Radiopharm Theranostics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 14,591 Radiopharm Theranostics shares in Q1 2026, an estimated $76K.
  • Virtu Financial first reported a position in Radiopharm Theranostics in Q4 2025 and held it in 1 quarter.
  • Virtu Financial's Radiopharm Theranostics position peaked at $76K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.